⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Microsoft Solutions Partner Aureus Intelligence AI Launches HyperScoper™ - First AI-Powered Instant Estimator for Power Platform and Copilot Projects in the UK
globenewswire.com
MSFT
JNJ
SHEL
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight
prnewswire.com
BIIB
IONS
ALNY
AZN
GILD
JNJ
BMRN
VRTX
ASTL
PFE
NVO
REGN
Coloplast appoints Gavin Wood as new CEO
globenewswire.com
JNJ
LexisNexis Recognizes Visionary Companies From 18 Countries as “Top 100 Global Innovators” for 2026
globenewswire.com
IBM
ADI
AMAT
AVGO
CDNS
CSCO
DELL
INTC
LRCX
MRVL
MU
NVDA
QCOM
SNPS
TXN
AMD
LLY
MRNA
BMY
GILD
PFE
JNJ
ABBV
AMGN
BIIB
REGN
VRTX
ADSK
GOOG
MSFT
ORCL
CRM
ADPT
ALGN
BKR
CTAS
DDOG
DXCM
EXPE
FIVN
FTNT
IDXX
ILMN
INTU
ISRG
JD
KDP
LULU
MCHP
MDLZ
MELI
MNST
NFLX
NOW
NTES
OKTA
ON
PANW
PAYX
PDD
PEP
PYPL
ROKU
SBUX
SMCI
SWKS
TEAM
TCOM
TDS
TER
TGT
TTEC
TTWO
TWLO
ULTA
VRSK
WDC
WEC
XRAY
ZBRA
ZM
ASML
KLAC
NXPI
AMZN
AAPL
GOOGL
META
TSLA
Z
KHC
CL
PG
COST
WMT
Global Peripheral Vascular Devices Market Poised for Robust Growth at a CAGR of ~6% Through 2032 as Demand for Minimally Invasive Treatments Surges | DelveInsight
prnewswire.com
MDT
BSX
EW
LMAT
ABT
PHG
BDX
PEN
JNJ
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
prnewswire.com
MLYS
PROK
IRON
REGN
AMGN
MAZE
LLY
JNJ
LXRX
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
prnewswire.com
JNJ
Drug Discovery Leader Marcus Schindler Joins Cradle's Advisory Board
prnewswire.com
JNJ
ABBV
NVO
Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer
businesswire.com
EW
JNJ
EcoVadis Launches Peer-to-Peer Community to Turn Sustainability Insight into Shared Progress
prnewswire.com
JNJ
UL
JPM